In a retrospective study on melanoma LM with a historically low overall survival (OS) rate of just 2 months, the use of BRAF/MEK inhibitors or ipilimumab resulted in a significantly higher OS rate than the overall cohort (21.7 weeks vs. 6.9 weeks) [141]. The gene discussed is MAP2K7; the disease is melanoma.